News
GSK's Jemperli/TIM-3 immuno-oncology combo moves to ph3
GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031.
